Rare Cancer News & Clinical Trials » PubMed

PubMed - Adenoid Cystic Carcinoma (100 unread)

1 2 3

Papillary variant of adenoid cystic carcinoma of the maxillary sinus

Fetched: January 13th, 2023, 2:04pm GMT by Junichi Shiraishi

Pathol Int. 2023 Jan 13. doi: 10.1111/pin.13307. Online ahead of print.

NO ABSTRACT

PMID:36636923 | DOI:10.1111/pin.13307
Posterior fossa giant adenoid cystic carcinoma with skull base invasion mimicking glomus jugulare: A case report and review of literature

Fetched: January 13th, 2023, 2:04pm GMT by Anand Kumar Das

Rare Tumors. 2023 Jan 6;15:20363613221150218. doi: 10.1177/20363613221150218. eCollection 2023.

ABSTRACT

The author describes a rare case of giant adenoid cystic carcinoma (ACC) mimicking large paraganglioma with lower cranial nerve palsy. A 60-year-old female presented with a progressive increase in postauricular swelling with unilateral hearing loss, facial deviation, difficulty in swallowing, and hoarseness of voice. MRI brain showed highly vascular infiltrating and osteolytic mass suggestive of large glomus jugulare versus sarcoma. It was completely engulfing the jugular foramen and lower cranial nerves with bony erosion of the jugular foramen and occipital condyle. The whole mastoid was filled with the tumor. On digital subtraction angiography the majority of blood supply was from the occipital branch of the external carotid artery and vertebral artery. The patient underwent percutaneous embolization followed by external carotid ligation and resection of the mass. The postoperative course was uneventful. Histopathology was suggestive of mixed ACCs. The patient received radiotherapy. After 1 year of follow up no recurrence or distant metastasis was noted.

PMID:36636105 | PMC:PMC9830093 | DOI:10.1177/20363613221150218
Solitary extramedullary plasmacytoma of the left main bronchus: A case report and literature review

Fetched: January 13th, 2023, 2:04pm GMT by Limin Gao

Thorac Cancer. 2023 Jan 12. doi: 10.1111/1759-7714.14790. Online ahead of print.

ABSTRACT

Tracheal tumors are rare, accounting for 0.1% of all malignancies. Squamous cell carcinoma and adenoid cystic carcinoma are the two most prevalent tracheal cancers. Less than 20 cases of extramedullary plasmacytoma in the trachea and main bronchus have ever been documented in the literature, making it extremely uncommon. Although the origin of these lesions is unclear, viral pathogenesis and persistent inflammation are thought to be the main causes. Clinically, these individuals exhibit vague symptoms such as stridor, a persistent cough, dyspnea, or wheezing, making a correct diagnosis difficult.

PMID:36635969 | DOI:10.1111/1759-7714.14790
Malignant adenomyoepithelioma of the breast: cases report and literature review

Fetched: January 12th, 2023, 5:00am GMT by Dandan Wang

Am J Transl Res. 2022 Dec 15;14(12):8788-8792. eCollection 2022.

ABSTRACT

BACKGROUND: Malignant adenomyoepithelioma (MAME) of the breast is an extremely rare breast malignancy, in which they arise from either luminal epithelial or myoepithelial components, or both. At present, there is very little clinical data of MAME.

CASE REPORT: We present two cases, one of them is a 34-year-old woman who underwent needle biopsy for a 3.2 cm-size mass in the right breast, and the pathology was MAME of breast. Another case is a 45-year-old woman who had a 3.0 cm-size mass in the right breast. We performed a breast-conserving surgery and sentinel lymph node biopsy, both of which were negative. The histopathology of these two cases was invasive carcinoma; however, these cases were eligible for MAME of the breast through combining with immunohistochemistry.

CONCLUSIONS: MAME of the breast is very rare, and has a diverse cell morphology, which must be combined with immunohistochemistry to make a clear diagnosis. Besides, it should be differentiated from adenoid cystic cancer, malignant leafy tumor, spindle cell carcinoma, etc. The clinical characteristics and treatment strategies were further discussed in combination with the literature.

PMID:36628238 | PMC:PMC9827327
Epidemiological and clinical characteristics of 407 salivary glands neoplasms in surgically treated patients in 2010-2020

Fetched: January 10th, 2023, 5:00am GMT by Weronika Jaremek-Ochniak

Otolaryngol Pol. 2022 Sep 9;76(5):29-36. doi: 10.5604/01.3001.0015.9816.

ABSTRACT

INTRODUCTION Tumors of the salivary glands account for approximately 3 to 4% of all head and neck neoplasms. It is estimated that 10-15% of them are malignant. The most common benign tumor is pleomorphic adenoma, while the most common malignant tumors are adenoid cystic carcinoma and mucoepidermoid carcinoma. Neoplasms of the salivary glands are extremely histologically diverse, which results from the complex embryogenesis of the salivary glands. The identified risk factors for tumors of the salivary glands are: ultraviolet radiation, ionizing radiation, viral infections, nicotine and alcohol. MATERIAL AND METHOD The aim of the study was an epidemiological analysis of patients with salivary gland neoplasms, the distribution and histopathological characteristics of individual neoplasms treated at the Department of Otorhinolaryngology of the Medical University of Warsaw in 2010-2020. The diagnoses were analyzed according to the latest WHO 2017 histological classification of salivary gland tumors. In addition, the material was supplemented with data on the 5-year survival rates of patients with malignant neoplasms obtained from the Registry of Marital Status. RESULTS AND DISCUSSION The material contained 407 neoplasms of the salivary glands over a 11-year period, of which malignant neoplasms accounted for 17.4%. The malignant tumors were dominated by: adenoid cystic carcinoma (28,2%), mucoepidermoid carcinoma (12,7%), and acinic cell carcinoma (9,9%). Lymphomas (15,5%) were also a large group. The benign neoplasms were dominated by pleomorphic adenoma (54.1%) and Warthin's tumor (36%). Tumors of the salivary gland the most often affected the parotid gland (92%). CONCLUSIONS The obtained data are consistent with the general epidemiological data described in the current literature.

PMID:36622126 | DOI:10.5604/01.3001.0015.9816
Commentary: Complexity in rare disease: A look at surgical outcomes in tracheobronchial adenoid cystic carcinoma

Fetched: January 9th, 2023, 5:00am GMT by Michael A Eisenberg

J Thorac Cardiovasc Surg. 2022 Dec 15:S0022-5223(22)01341-1. doi: 10.1016/j.jtcvs.2022.12.005. Online ahead of print.

NO ABSTRACT

PMID:36609126 | DOI:10.1016/j.jtcvs.2022.12.005
Analysis of Cytological Misdiagnosis and Oversight of Adenoid Cystic Carcinoma of Salivary Gland

Fetched: January 3rd, 2023, 5:00am GMT by Cong-Gai Huang

Cancer Control. 2023 Jan-Dec;30:10732748221131652. doi: 10.1177/10732748221131652.

ABSTRACT

OBJECTIVE: In this article on adenoid cystic carcinoma (ACC) of salivary gland, we intend to summarize the causes of misdiagnosis and oversight of ACC hoping to improve cytological diagnostic accuracy, clinical management and patient treatment.

METHODS: The study retrospectively reviewed 32 patients with ACC of salivary gland, registered at the Affiliated Hospital of Southwest Medical University from July 2014 to June 2021. These cases were diagnosed by FNA and surgical excision biopsy. All cytopathological results were retrospectively categorized according to Milan system for reporting salivary gland cytopathology (MSRSGC). The accuracy of FNA was verified by surgical excision biopsy.

RESULTS: Of these 32 patients, 16 (50.0%) cases were male, and 16 (50.0%) were female. Their age ranged from 21 to 79 years, with an average age of 50.32 years. The highest incidence (15/32, 46.9%) of ACC was observed in patients between 41 and 50 years of age. 10 cases (31.3%) occurred in the parotid gland, 9 cases (28.1%) in the submandibular gland, 9 cases (28.1%) in the sublingual gland, 3 cases (9.4%) in the palate, and 1 case (3.1%) in the lip. Among the 32 cases of ACC, 23 cases (71.9%) were classified to VI, 4 cases (12.5%) to IVa, and 5 cases (15.6%) to II by MSRSGC. A comparison of the FNA results with biopsy showed that the accuracy of FNA in ACC of salivary gland is 71.9%. Being able to identify the cytomorphological features is the key factor for accurate diagnosis of ACC of the salivary gland.

CONCLUSION: Our results confirm that FNA is an important initial screening in the diagnosis of ACC of salivary gland. Increased study of the cytomorphology of ACC is beneficial for more accurate diagnosis of ACC, to reduce misdiagnosis and oversight.

PMID:36592477 | PMC:PMC9829876 | DOI:10.1177/10732748221131652
High-risk subtype: Clinical manifestations and molecular characteristics of submandibular gland adenoid cystic carcinoma

Fetched: January 3rd, 2023, 5:00am GMT by Mengjiao Zhou

Front Oncol. 2022 Dec 16;12:1021169. doi: 10.3389/fonc.2022.1021169. eCollection 2022.

ABSTRACT

OBJECTIVE: Adenoid cystic carcinoma of the head and neck mainly occurs in the major salivary glands, of which the parotid gland and submandibular gland are the most common. The purpose of this study was to clarify the site-specific differences in prognosis and molecular expression characteristics of the patients and to achieve stratified risk management of the clinical prognosis.

MATERIALS: By performing a single-centre retrospective analysis combined with analyses of the Surveillance, Epidemiology, and End Results (SEER) database, cBioPortal and GEO databases, the clinical prognostic characteristics and the differences in molecular expression patterns of ACC in the submandibular gland and parotid gland were analysed. Cox regression analysis, the chi-square test, Fisher's test and the log-rank test were used to compare the significance of differences.

RESULTS: Compared with patients with parotid gland ACC, the submandibular gland ACC is more likely to have metastases in the cervical lymph node (21.7% vs. 3.3%) and shows a higher rate of distant metastasis within 1 year after the primary site diagnosis (47.8% vs. 23.3%), a worse overall prognosis, more frequent mutations of MYB/MYBL1 (50% vs. 25%) and abnormal upregulation of the phosphatidylinositol-3 kinase (PI3K) pathway.

CONCLUSIONS: Submandibular gland ACC is associated with site-specific early cervical lymph node metastasis and hidden distant metastasis, along with rapid progression and a poor prognosis. A high MYB/MYBL1 mutation rate and abnormal upregulation of the PI3K pathway with MYB involvement were identified.

PMID:36591454 | PMC:PMC9800506 | DOI:10.3389/fonc.2022.1021169
MiR-29a-3p inhibits high-grade transformation and epithelial-mesenchymal transition of lacrimal gland adenoid cystic carcinoma by targeting Quaking

Fetched: December 28th, 2022, 5:00am GMT by Fei Xu

Mol Biol Rep. 2022 Dec 28. doi: 10.1007/s11033-022-08150-1. Online ahead of print.

ABSTRACT

BACKGROUND: Lacrimal adenoid cystic carcinoma (LACC) is the most common orbital malignant epithelial neoplasm. LACC with high-grade transformation (LACC-HGT) has higher rates of recurrence, metastasis, and mortality than LACC without HGT. This study investigated the effects of microRNA-29a-3p (miR-29a-3p) in the pathogenesis of LACC-HGT.

METHODS: An Agilent human miRNA microarray was used to screen the differentially expressed miRNAs (DEMs) in LACC and LACC-HGT tumor tissues. Then, the primary cells obtained in previous studies were used to determine the effect of miR-29a-3p.

RESULTS: The expression of miR-29a-3p was abnormally lower in LACC-HGT than in LACC. miR-29a-3p can specifically target the 3' UTR of Quaking mRNA and down-regulate Quaking expression, thereby inhibiting the proliferation, migration, and epithelial-mesenchymal transition of LACC cells.

CONCLUSIONS: This study illustrated that miR-29a-3p functions as a tumor suppressor by down-regulating the expression of Quaking to inhibit the tumorigenesis of LACC cells. This study may also reveal the pathogenesis of HGT in LACC cells and provide a reference for LACC-HGT targeted diagnosis.

PMID:36575320 | DOI:10.1007/s11033-022-08150-1
Tracheobronchial adenoid cystic carcinoma mimicking bronchial asthma

Fetched: December 27th, 2022, 5:00am GMT by H Ishikawa

J Postgrad Med. 2023 Jan-Mar;69(1):56-58. doi: 10.4103/jpgm.jpgm_201_22.

NO ABSTRACT

PMID:36571332 | DOI:10.4103/jpgm.jpgm_201_22
Adenoid cystic carcinoma of submandibular gland: emphasis on locoregional metastasis and prognosis

Fetched: December 25th, 2022, 5:00am GMT by Shengwen Liu

Oral Dis. 2022 Dec 23. doi: 10.1111/odi.14478. Online ahead of print.

ABSTRACT

OBJECTIVES: To analyze the clinicopathological features, locoregional or distant metastasis, and prognosis of adenoid cystic carcinoma of submandibular gland (SMG-AdCC).

METHODS: The clinicopathological data of 80 patients with SMG-AdCC from January 2005 to December 2017 were analyzed retrospectively, and the relationships between different parameters of SMG-AdCC and its locoregional or distant metastasis or prognosis were analyzed.

RESULTS: As of December 2019, 41 patients (51.25%) were tumor-free, while 20 patients were found to be living with tumors. The locoregional metastasis rate of grade II-III SMG-AdCC were found to be significantly higher than that of grade I. The five-year DFS and OS rates were 70.8% and 87.1%, respectively. Univariate analysis showed that clinical size, extraglandular extension, pathological grade, pathological node (pN) status, and perineural invasion were correlated with DFS. Multivariate Cox regression analysis showed that pathological grade and extraglandular extension were independent prognostic factors for DFS; pN status and extraglandular extension were independent prognostic factors impacting OS.

CONCLUSION: The pathological grade is a risk factor for locoregional metastasis of SMG-AdCC. Pathological grade, pN status, and status of extraglandular extension are independent prognostic factors for DFS/OS in SMG-AdCC patients.

PMID:36564993 | DOI:10.1111/odi.14478
A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers

Fetched: December 23rd, 2022, 5:00am GMT by Wenna Zhang

Ann Transl Med. 2022 Nov;10(22):1192. doi: 10.21037/atm-20-7760.

ABSTRACT

BACKGROUND: To present and analyze the current status of registered clinical trials on particle beam (including proton and carbon ion beam) radiation therapy (PBRT) for head and neck (H&N) malignancies, and to provide insights for future clinical research, we designed the cross-sectional analysis.

METHODS: We identified and analyzed all clinical trials of interest registered on ClinicalTrials.gov and PTCOG.ch until March 22, 2020.

RESULTS: We identified 57 registered clinical trials related to the use of proton therapy or carbon ion radiation therapy (CIRT) in H&N malignancies. There were 20, 27, and 5 trials focused on CIRT, proton therapy, and both ions, respectively. The eligible trials were registered between 2007 and 2020, mainly focused on adenoid cystic carcinoma (ACC), squamous cell carcinoma (SCC), sinonasal malignancies (SNM), skull base tumors, locally advanced, and recurrent tumors. The nature of 23 (40%) trials were not stated and could not be identified. A total of 25 (44%) registered trials were phase II, including randomized controlled trials (RCTs). There were 14 RCTs (7 phase II, 2 phase II/III, 2 phase III, 1 phase I/II, and 2 phase not applicable), and 25 studies including RCTs were registered before the first enrolment. There were 11 completed clinical trials among the eligible trials, including 7 with published trial-related results.

CONCLUSIONS: Less than 10% of the countries with PBRT treatment facilities in operation have initiated clinical trials on H&N cancer. Furthermore, among all registered trials, less than 10% have been completed with results published. More clinical trials, especially high quality trials, are needed for optimizing and standardizing treatment techniques of PBRT for H&N malignancies.

PMID:36544687 | PMC:PMC9761119 | DOI:10.21037/atm-20-7760
The role of carbon-ion radiotherapy in the treatment of adenoid cystic carcinoma of the nasopharynx

Fetched: December 23rd, 2022, 5:00am GMT by Jiyi Hu

Ann Transl Med. 2022 Nov;10(22):1198. doi: 10.21037/atm-20-1767.

ABSTRACT

BACKGROUND: Nasopharyngeal adenoid cystic carcinoma (NACC) is a distinct subgroup of adenoid cystic carcinoma (ACC) with limited surgical access but predilection of regional and distant metastasis. Although radiotherapy is an integral treatment for patients with NACC, photon-based radiotherapy yielded suboptimal local control. Because of its advantages in biology and physics properties, carbon-ion radiotherapy (CIRT) was attempted for the treatment of head and neck ACC; however, the use of CIRT specifically for NACC has not been investigated.

METHODS: Patients with NACC that received CIRT alone or a combination of CIRT and proton beam therapy (PBT) at the Shanghai Proton and Heavy Ion Center (SPHIC) between July 2016 and March 2019 were included in the analysis. Patients with newly diagnosed NACC received combined therapy of CIRT (as boost) and PBT, and those with recurrent disease received CIRT alone. Overall survival (OS), local progression-free survival (LPFS), regional progression-free survival (RPFS), and distant metastasis-free survival (DMFS) were calculated by Kaplan-Meier method.

RESULTS: A total of 22 patients were included in this analysis. Among those, 18 patients had newly diagnosed NACC (17 with locally advanced disease), and 4 had recurrent NACC including 2 failed previous irradiation. After a median follow-up of 30.9 months, the 2-year OS rate, PFS rate, LPFS rate, RPFS rate and DMFS rate were 100%, 84.8%, 94.4%, 100%, and 84.8%, respectively. Three patients experienced grade 3 mucositis or xerostomia. No late toxicity of grade ≥3 was observed.

CONCLUSIONS: CIRT alone or in combination with PBT appeared to be a promising modality for the treatment of NACC and produced satisfactory local disease control and toxicity profile. Distant metastasis remained to be a substantial mode for treatment failure. Further follow-up is necessary to evaluate long-term survivals and late toxicity profile.

PMID:36544666 | PMC:PMC9761180 | DOI:10.21037/atm-20-1767
Extracellular Vesicles from Carcinoma-associated Fibroblasts Promote EMT of Salivary Adenoid Cystic Carcinoma Via IL-6

Fetched: December 22nd, 2022, 5:00am GMT by Hyat Ahmed Ibrahim Al-Raimi

Arch Med Res. 2022 Dec 19:S0188-4409(22)00182-5. doi: 10.1016/j.arcmed.2022.12.005. Online ahead of print.

ABSTRACT

BACKGROUND: Carcinoma-associated fibroblasts (CAFs) play a pivotal role in cancer progression. Salivary adenoid cystic carcinoma (SACC) has a high tendency to invade and metastasize. Understanding how CAFs interact with SACC cells is essential for developing new targeted therapies for SACC. Extracellular vesicles (EVs) play important roles in intercellular communication. However, the role of CAFs-derived EVs in SACC invasion remains poorly understood.

AIM OF THE STUDY: To show that CAFs EVs are involved in the EMT of SACC and promote tumor invasion.

METHODS: CAFs-derived EVs were characterized by western blot and transmission electron microscopy. Wound healing and transwell assay were performed for assessing biological foundation of CAFs-EVs for tumor cells. RNA interference transfection, western blot, wound healing and transwell assay were applied to study the effect of IL6 from CAFs-EVs on SACC cells and the mechanism. A subcutaneous xenograft model was used to evaluate the EMT of SACC induced by CAFs in vivo.

RESULTS: In this study, we show that CAFs EVs promote the migration and invasion of SACC cells. The expression of biomarkers of epithelial-mesenchymal transition (EMT) was higher in SACC cells treated with CAFs EVs than in the negative controls, and high levels of IL6 were detected in CAFs and their EVs. Knockdown of IL6 in CAFs decreased tissue invasiveness and EMT biomarker expression in SACC cells induced by CAFs EVs. CAFs EV-associated IL6 promoted SACC EMT by activating the JAK2/STAT3 signaling pathway.

CONCLUSION: CAFs-derived EVs carry IL6 to improve EMT of SACC by activating the JAK2/STAT3 signaling pathway.

PMID:36543625 | DOI:10.1016/j.arcmed.2022.12.005
Salivary gland carcinomas - Monocentric experience on subtypes and their incidences over 42 years

Fetched: December 22nd, 2022, 5:00am GMT by Christian Krauss

Laryngorhinootologie. 2022 Dec 21. doi: 10.1055/a-1976-9694. Online ahead of print.

ABSTRACT

OBJECTIVE: Salivary gland carcinomas are rare and heterogeneous. More than 20 subtypes are recognized and risk factors are diverse. The aim of this work was to evaluate the subtype and other risk factors in a monocentric population from more than four decades.

MATERIAL AND METHODS: 205 cases (diagnosis period 1972-2014) were retrospectively collected and analyzed with regard to the distribution of risk factors and their influence on overall survival (OS).

RESULTS: 19/24 (79.2%) of the subtypes listed in the WHO classification occurred rarely in the cohort (< 5%). 10/24 (41.7%) of all subtypes were never diagnosed. With a total of 145/205 cases (70.7%), squamous cell carcinoma (PEC), adenocarcinoma (AdenoCa), acinar cell carcinoma (AcinarCa), mucoepidermoid carcinoma (MEC), and adenoid cystic carcinoma (ACC) were by far the most common subtypes. Risk factors are significantly different in these groups (e.g., lymphogenic metastasis and degree of differentiation in AdenoCa and age, T and UICC stage in PEC). The 5-year overall survival of all patients was 66.9% and differed significantly within the most common subtypes. An independent impact on overall survival was detectable for patient age (p<0.001), and T- (p=0.003) and N-stage (p=0.046) in multivariate analysis.

CONCLUSIONS: Most subtypes occurred markedly rarely or not at all within decades. The most common diagnoses differ with respect to risk factors as well as OS and 3 risk groups can be defined based on histology. In conclusion, considering TNM alone is insufficient for prognosis estimation in salivary gland carcinoma.

PMID:36543220 | DOI:10.1055/a-1976-9694
One stage reconstruction of mid-face fistulous defects after maxillary sinus carcinoma resection with chimeric perforator free flaps

Fetched: December 20th, 2022, 5:00am GMT by Yudi Han

Microsurgery. 2022 Dec 18. doi: 10.1002/micr.30996. Online ahead of print.

ABSTRACT

BACKGROUND: The reconstruction of large fistulous defects following the radical ablation of maxillary sinus carcinoma remains challenging. The procedure requires not only the coverage of both intra-nasal lining and cheek skin but also sufficient obliteration of dead space between the two surfaces. In this report, we present our experience on the reconstruction of through-and-through defects in the mid-face with poly-foliated chimeric perforator flaps.

METHODS: Nine patients (five males and four females) who received a two-skin paddled and one muscle segment chimeric perforator flap reconstruction after maxillary sinus carcinoma ablation between March 2015 and December 2019 were retrospectively reviewed in authors' hospital. The mean age of the patients was 59.11. Six patients were diagnosed as squamous cell carcinoma, two as adenoid cystic carcinoma, and one as adenocarcinoma. Brown class IIIa defects were found in eight patients, and one patient had a Brown class IVa defect. The mean size of intra-nasal defect was 5.67 × 4.06 cm² , and the mean size of facial skin defect was 8.94 × 6.56 cm² . ALT flaps were used in five patients, LD flaps in four patients. The minor skin paddle was firstly inset to the mucosal defect site as the lining. Then, the muscle segment was inset to eliminate the dead cavity. Finally, the major skin paddle was inset to recover the cutaneous defect.

RESULTS: In ALT group, the mean size of the minor skin paddle was 5.7 × 4.7 cm² , and the mean size of the major skin paddle was 8.7 × 6.6 cm² . In LD group, the mean size of the minor skin paddle was 6.88 × 4.38 cm² , and the mean size of the major skin paddle was 11 × 7.75 cm² .All donor sites were closed primarily. All flaps survived and no partial flap loss was encountered. The mean follow-up time was 14.67 months, and there were no major postoperative complications.

CONCLUSION: The use of poly-foliated chimeric perforator free flaps can provide functional and aesthetic coverage for extensive through-and-through mid-face defects without significant donor-site morbidities.

PMID:36530044 | DOI:10.1002/micr.30996
Retrospective study of outcomes after extended resection for tracheobronchial adenoid cystic carcinoma

Fetched: December 18th, 2022, 5:00am GMT by Jérôme Estephan

J Thorac Cardiovasc Surg. 2022 Nov 8:S0022-5223(22)01171-0. doi: 10.1016/j.jtcvs.2022.10.048. Online ahead of print.

ABSTRACT

OBJECTIVE: Tracheobronchial adenoid cystic carcinoma is a rare, slow-growing malignancy with a considerable propensity for local extension that may require complex airway resection to achieve tumor-free margins. The objective of this study was to assess whether our experience supports complex airway resection for tracheobronchial adenoid cystic carcinoma.

METHODS: Consecutive patients who underwent curative resection for tracheobronchial adenoid cystic carcinoma at our institution between 1970 and 2019 were included retrospectively and classified as having had complex or standard resection. Complex surgery included total tracheal replacement, associated esophageal resection, pneumonectomy, total laryngectomy with tracheal resection, and carinal resection. Standard surgery included tracheal resection, bronchoplastic resection, lobectomy, and bilobectomy. We obtained data from medical records, referring physicians, patients, relatives, and public death records.

RESULTS: Of 59 included patients, 38 had complex and 21 had standard surgery. All 4 (6.8%) patients who died postoperatively had undergone complex surgery. Postoperative morbidity was 32.2% overall and was significantly higher after complex surgery (P = .043). Overall 5- and 10-year survival rates were 81.5% and 60.2%, with no significant differences between groups (P = .31). By univariate analysis, T4 tumor and microscopically detectable tumor in the operative specimen margins and gross tumor in the operative specimen margins were associated with poorer survival (P < .05). In the subgroup with microscopically detectable tumor resection, survival was significantly better with adjuvant radiotherapy (P < .05).

CONCLUSIONS: Complex resection for extended tracheobronchial adenoid cystic carcinoma may achieve local control and satisfying long-term survival. However, this demanding procedure is associated with high postoperative morbidity and mortality rates. Because adjuvant radiotherapy improved outcomes after resection resulting in microscopically detectable tumor in the operative specimen margins, expected outcomes after resection with no detectable tumor in the margins must be compared to those after resection resulting in microscopically detectable tumor in the margins plus radiotherapy, according to the operative risk.

PMID:36528436 | DOI:10.1016/j.jtcvs.2022.10.048
Sebaceous Differentiation as Another Feature of Metatypical Adenoid Cystic Carcinoma: A Case Report and Letter to the Editor

Fetched: December 17th, 2022, 5:00am GMT by Kaitlyn D W Ooms

Am J Surg Pathol. 2023 Jan 1;47(1):145-146. doi: 10.1097/PAS.0000000000001993. Epub 2022 Nov 1.

NO ABSTRACT

PMID:36525543 | DOI:10.1097/PAS.0000000000001993
Prognostic effects of surgery or radiotherapy on adenoid cystic carcinoma of the head and neck: a retrospective cohort study

Fetched: December 16th, 2022, 5:00am GMT by Bing Zhang

Gland Surg. 2022 Nov;11(11):1784-1794. doi: 10.21037/gs-22-526.

ABSTRACT

BACKGROUND: There is little evidence exploring prognostic effects of surgery and radiotherapy on adenoid cystic carcinoma (ACC) of the head and neck. This study sought to evaluate the prognostic effects of surgery or radiotherapy on ACC of the salivary gland, oropharynx, and nose, nasal cavity, and middle ear.

METHODS: In this cohort study, the data of 2,392 participants with ACC of the head and neck were extracted from the Surveillance, Epidemiology and End Results (SEER) database. Participants were divided into the salivary gland group (n=1,351), the mouth and oropharynx group (n=563), and the nose, nasal cavity, and middle ear group (n=478). Baseline characteristics were assessed via questionnaires or laboratory analysis and outcome variables were all-cause death and cancer-specific death of patients. Baseline data were collected in 2004, and patients were followed-up to 2016. The survival time of patients were recorded. Univariate and multivariate Cox regression analyses explored the effects of surgery and radiotherapy on overall prognosis of ACC patients. Fine-Gray test assessed the effects of surgery and radiotherapy on cancer-specific mortality of ACC patients.

RESULTS: In total, 766 died and 1,626 survived with a median survival time of 9.92 years. After adjusting for confounders, patients with ACC of the salivary gland who underwent surgery had a decreased risk of all-cause mortality [hazard ratio (HR) =0.51; 95% confidence interval (CI): 0.36-0.71] and cancer-specific mortality (HR =0.57; 95% CI: 0.34-0.97). Surgery was found to be a protective factor for the risk of all-cause mortality (HR =0.47; 95% CI: 0.28-0.78) and cancer-specific mortality (HR =0.70; 95% CI: 0.33-1.50) of patients with ACC of the mouth and oropharynx after adjusting for confounders. After adjusting for confounders, patients with ACC of the nose, nasal cavity, and middle ear who underwent surgery had a decreased risk of all-cause mortality (HR =0.46; 95% CI: 0.30-0.70) and cancer-specific mortality (HR =0.35; 95% CI: 0.20-0.61).

CONCLUSIONS: Surgery was associated with a decreased risk of mortality in patients with ACC of the salivary gland, oropharynx, and nose, nasal cavity, and middle ear, which suggested the value of surgery for improving their prognosis.

PMID:36518804 | PMC:PMC9742048 | DOI:10.21037/gs-22-526
Endoscopic Management of Malignant Tumors of Paranasal Sinus and Nasal Cavity: An Institutional Experience

Fetched: December 16th, 2022, 5:00am GMT by Rajat Jain

Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(4):564-574. doi: 10.1007/s12070-022-03141-x. Epub 2022 Sep 9.

ABSTRACT

Malignant tumors of sinonasal region are rare and affect less than 1 in 100,000 people per year. They are histologically diverse group and potentially pose significant management problems due to their proximity to the orbit and intracranial cavity. Although squamous cell carcinoma (SCC) is most common malignant tumor of paranasal cavity, tumors like adenocarcinoma, olfactory neuroblastoma, malignant melanoma, adenoid cystic carcinoma, sarcomas, haemoproliferative tumors, e.g. lymphoma may also occur. Retrospectively study was done in a tertiary care institute from January 2008 to December 2018 in India. Inclusion criteria-all biopsy proven PNS malignancy patients operated by endoscopic approach, irrespective of age and gender. Exclusion criteria- patients diagnosed with nasopharyngeal carcinoma, skin involvement, gross orbital involvement (muscle invasion), metastasis, operated by open approaches. 46 patients who underwent endoscopic tumor removal were reviewed. 36 (78.2%) were males and 10 (4.6%) females. Most common tumor in our study was adenoid cystic carcinoma. Recurrence was seen in 6 patients. Palliative therapy was given to all patients with recurrence. Management of malignant PNS tumor involving anterior skull base is multidisciplinary. R0 resection should be main goal in all malignant PNS malignancy. Tumors invading unresectable areas like cavernous sinus, brain parenchyma, carotids can be left in these places followed by palliation except in cases of squamous cell carcinoma. If R0 cannot be achieved surgically in SCC than patient should be considered inoperable and send for palliation. T1-T3 PNS malignant tumors can be managed by endoscopic approach followed by adjuvant therapy after a period of 6 weeks. Endoscopic excision should be converted to endoscopic assisted open approach in case of T4 tumors. We have tried to give a management protocol for management of malignant PNS tumors. Level of evidence: II.

PMID:36514438 | PMC:PMC9741682 | DOI:10.1007/s12070-022-03141-x
Drug Screening Using Novel IMD in ACC and Salivary Cancers

Posted: September 23rd, 2022, 2:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Adenoid Cystic Carcinoma of the Salivary Gland
Intervention: Combination Product: Implantable Microdevice (IMD)
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation
Not yet recruiting
Drug Screening Using Novel IMD in ACC and Salivary Cancers

Posted: September 23rd, 2022, 2:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Adenoid Cystic Carcinoma of the Salivary Gland
Intervention: Combination Product: Implantable Microdevice (IMD)
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation
Not yet recruiting
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Posted: August 12th, 2022, 2:00pm GMT

Conditions: 68Ga-FAPI PET/CT; Metastatic Adenoid Cystic Carcinoma
Intervention: Drug: 68Ga-FAPI
Sponsor: Peking Union Medical College Hospital
Recruiting
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Posted: August 12th, 2022, 2:00pm GMT

Conditions: 68Ga-FAPI PET/CT; Metastatic Adenoid Cystic Carcinoma
Intervention: Drug: 68Ga-FAPI
Sponsor: Peking Union Medical College Hospital
Recruiting
A Study of SGN-B7H4V in Advanced Solid Tumors

Posted: January 18th, 2022, 3:00pm GMT

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: SGN-B7H4V
Sponsor: Seagen Inc.
Recruiting
A Study of SGN-B7H4V in Advanced Solid Tumors

Posted: January 18th, 2022, 3:00pm GMT

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: SGN-B7H4V
Sponsor: Seagen Inc.
Recruiting
Amivantamab in Adenoid Cystic Carcinoma

Posted: October 12th, 2021, 2:00pm GMT

Condition: Salivary Gland Cancer
Intervention: Drug: Amivantamab
Sponsor: Trisha Wise-Draper
Recruiting
Amivantamab in Adenoid Cystic Carcinoma

Posted: October 12th, 2021, 2:00pm GMT

Condition: Salivary Gland Cancer
Intervention: Drug: Amivantamab
Sponsor: Trisha Wise-Draper
Recruiting
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Posted: August 18th, 2021, 2:00pm GMT

Conditions: Salivary Gland Cancer; Recurrent Salivary Gland Cancer; Metastatic Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsors: Glenn J. Hanna; Actuate Therapeutics Inc.
Recruiting
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Posted: August 18th, 2021, 2:00pm GMT

Conditions: Salivary Gland Cancer; Recurrent Salivary Gland Cancer; Metastatic Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsors: Glenn J. Hanna; Actuate Therapeutics Inc.
Recruiting
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Posted: July 23rd, 2021, 2:00pm GMT

Condition: Carcinoma, Adenoid Cystic
Intervention: Drug: EGFR-TK Inhibitor
Sponsor: Qingdao Central Hospital
Recruiting
Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Posted: July 23rd, 2021, 2:00pm GMT

Condition: Carcinoma, Adenoid Cystic
Intervention: Drug: EGFR-TK Inhibitor
Sponsor: Qingdao Central Hospital
Recruiting
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Posted: July 22nd, 2021, 2:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Drug: AL101; Procedure: Therapeutic Conventional Surgery
Sponsor: M.D. Anderson Cancer Center
Recruiting
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Posted: July 22nd, 2021, 2:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Drug: AL101; Procedure: Therapeutic Conventional Surgery
Sponsor: M.D. Anderson Cancer Center
Recruiting
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Posted: May 12th, 2021, 2:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Other: Standard of Care; Radiation: SBRT
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation; Gateway for Cancer Research
Recruiting
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial

Posted: May 12th, 2021, 2:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Other: Standard of Care; Radiation: SBRT
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation; Gateway for Cancer Research
Recruiting
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Posted: April 5th, 2021, 2:00pm GMT

Conditions: Salivary Gland Carcinoma; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Salivary Gland Neoplasms
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsor: Actuate Therapeutics Inc.
Withdrawn
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Posted: April 5th, 2021, 2:00pm GMT

Conditions: Salivary Gland Carcinoma; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Salivary Gland Neoplasms
Interventions: Drug: 9-ING-41; Drug: Carboplatin
Sponsor: Actuate Therapeutics Inc.
Withdrawn
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617

Posted: March 16th, 2021, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Drug: 68Ga-PSMA; Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Sponsor: Peking Union Medical College Hospital
Recruiting
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617

Posted: March 16th, 2021, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Drug: 68Ga-PSMA; Drug: 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
Sponsor: Peking Union Medical College Hospital
Recruiting
Understanding the Burden of ACC Through the Eyes of Patients

Posted: January 13th, 2021, 3:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention:
Sponsors: Ayala Pharmaceuticals, Inc,; Adenoid Cystic Carcinoma Research Foundation; Memorial Sloan Kettering Cancer Center; Hadassah Medical Organization; Engage Health Inc.
Unknown status
Understanding the Burden of ACC Through the Eyes of Patients

Posted: January 13th, 2021, 3:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention:
Sponsors: Ayala Pharmaceuticals, Inc,; Adenoid Cystic Carcinoma Research Foundation; Memorial Sloan Kettering Cancer Center; Hadassah Medical Organization; Engage Health Inc.
Unknown status
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Posted: June 16th, 2020, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma of the Head and Neck
Interventions: Drug: All-trans Retinoic Acid; Drug: VEGFR inhibitor; Drug: Chemotherapy
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Posted: June 16th, 2020, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma of the Head and Neck
Interventions: Drug: All-trans Retinoic Acid; Drug: VEGFR inhibitor; Drug: Chemotherapy
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Posted: March 2nd, 2020, 3:00pm GMT

Conditions: Salivary Gland Cancer; Salivary Duct Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: Lutetium-177-PSMA-I&T
Sponsors: Radboud University Medical Center; Dutch Cancer Society
Recruiting
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Posted: March 2nd, 2020, 3:00pm GMT

Conditions: Salivary Gland Cancer; Salivary Duct Carcinoma; Adenoid Cystic Carcinoma
Intervention: Drug: Lutetium-177-PSMA-I&T
Sponsors: Radboud University Medical Center; Dutch Cancer Society
Recruiting
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Posted: January 31st, 2020, 3:00pm GMT

Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsor: Poseida Therapeutics, Inc.
Active, not recruiting
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Posted: January 31st, 2020, 3:00pm GMT

Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsor: Poseida Therapeutics, Inc.
Active, not recruiting
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

Posted: January 2nd, 2020, 3:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Carbon ion irradiation; Radiation: Bimodal irradiation
Sponsor: Heidelberg University
Recruiting
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

Posted: January 2nd, 2020, 3:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Carbon ion irradiation; Radiation: Bimodal irradiation
Sponsor: Heidelberg University
Recruiting
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Posted: December 24th, 2019, 3:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Salivary Gland Cancer
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Eisai Inc.
Recruiting
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Posted: December 24th, 2019, 3:00pm GMT

Conditions: Adenoid Cystic Carcinoma; Salivary Gland Cancer
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Eisai Inc.
Recruiting
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Posted: October 28th, 2019, 2:00pm GMT

Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
Interventions: Drug: ONC-392; Drug: Pembrolizumab
Sponsors: OncoC4, Inc.; National Cancer Institute (NCI)
Recruiting
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Posted: October 28th, 2019, 2:00pm GMT

Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
Interventions: Drug: ONC-392; Drug: Pembrolizumab
Sponsors: OncoC4, Inc.; National Cancer Institute (NCI)
Recruiting
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Posted: October 8th, 2019, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Rivoceranib
Sponsor: Elevar Therapeutics
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Posted: October 8th, 2019, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Rivoceranib
Sponsor: Elevar Therapeutics
Active, not recruiting
The Registry of Oncology Outcomes Associated With Testing and Treatment

Posted: July 22nd, 2019, 2:00pm GMT

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Recruiting
The Registry of Oncology Outcomes Associated With Testing and Treatment

Posted: July 22nd, 2019, 2:00pm GMT

Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; Liver Cancer; Hepatic Cancer; Melanoma; Skin Cancer; Unknown Primary Tumors; Uterine Cancer; Fallopian Tube Cancer; Ovarian Cancer; Prostate Cancer; Vaginal Cancer; Penile Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; Cancer, Advanced; Thymus Cancer; Nasopharyngeal Carcinoma; Multiple Endocrine Neoplasia; Pheochromocytoma; Small Cell Carcinoma; Pulmonary Carcinoma
Interventions: Diagnostic Test: Biomarker Testing (L); Drug: Systemic Treatment (T); Other: Patient Reported Outcomes (P)
Sponsor: Taproot Health
Recruiting
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Posted: June 27th, 2019, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Tretinoin
Sponsors: Dana-Farber Cancer Institute; The V Foundation; Adenoid Cystic Carcinoma Research Foundation
Completed
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma

Posted: June 27th, 2019, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Tretinoin
Sponsors: Dana-Farber Cancer Institute; The V Foundation; ACCRF
Completed
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Posted: June 19th, 2019, 2:00pm GMT

Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Posted: June 19th, 2019, 2:00pm GMT

Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Posted: March 22nd, 2019, 2:00pm GMT

Conditions: Relapsed/Refractory Advanced Solid Tumors; Relapsed/Refractory Diffuse Large B-cell Lymphoma; Relapsed/Refractory Myelodysplasia; Relapsed/Refractory Myelofibrosis; Adenoid Cystic Carcinoma; Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia
Intervention: Drug: PRT543
Sponsor: Prelude Therapeutics
Completed
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Posted: March 22nd, 2019, 2:00pm GMT

Conditions: Relapsed/Refractory Advanced Solid Tumors; Relapsed/Refractory Diffuse Large B-cell Lymphoma; Relapsed/Refractory Myelodysplasia; Relapsed/Refractory Myelofibrosis; Adenoid Cystic Carcinoma; Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia
Intervention: Drug: PRT543
Sponsor: Prelude Therapeutics
Completed
APG-115 in Salivary Gland Cancer Trial

Posted: December 20th, 2018, 3:00pm GMT

Conditions: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Interventions: Drug: APG-115; Drug: Carboplatin
Sponsors: University of Michigan Rogel Cancer Center; Ascentage Pharma Group Inc.
Recruiting
APG-115 in Salivary Gland Cancer Trial

Posted: December 20th, 2018, 3:00pm GMT

Conditions: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Interventions: Drug: APG-115; Drug: Carboplatin
Sponsors: University of Michigan Rogel Cancer Center; Ascentage Pharma Group Inc.
Recruiting
A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Posted: October 1st, 2018, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AL101
Sponsor: Ayala Pharmaceuticals, Inc,
Active, not recruiting
A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Posted: October 1st, 2018, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AL101
Sponsor: Ayala Pharmaceuticals, Inc,
Active, not recruiting
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)

Posted: August 21st, 2018, 2:00pm GMT

Conditions: Adenoid Cystic Carcinomas; Cisplatin
Intervention: Drug: Chidamide combined with cisplatin
Sponsor: Fudan University
Completed
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)

Posted: August 21st, 2018, 2:00pm GMT

Conditions: Adenoid Cystic Carcinomas; Cisplatin
Intervention: Drug: Chidamide combined with cisplatin
Sponsor: Fudan University
Completed
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Posted: June 14th, 2018, 2:00pm GMT

Conditions: Any Solid Tumors; Mesothelioma; Head and Neck Squamous Cell Carcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Squamous Cell Carcinoma of Lung; Esophageal Cancer; Adenoid Cystic Carcinoma; Prostate Cancer; Cervical Cancer; Gastric Cancer; Melanoma; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Thymic Carcinoma and Thymoma; Progressor of Anti PD-1/PD-L1 Immunotherapy
Intervention: Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsor: VM Oncology, LLC
Recruiting
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Posted: June 14th, 2018, 2:00pm GMT

Conditions: Any Solid Tumors; Mesothelioma; Head and Neck Squamous Cell Carcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Squamous Cell Carcinoma of Lung; Esophageal Cancer; Adenoid Cystic Carcinoma; Prostate Cancer; Cervical Cancer; Gastric Cancer; Melanoma; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Thymic Carcinoma and Thymoma; Progressor of Anti PD-1/PD-L1 Immunotherapy
Intervention: Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsor: VM Oncology, LLC
Recruiting
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Posted: February 6th, 2018, 3:00pm GMT

Conditions: Breast Cancer; Colorectal Cancer; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant; Hepatocellular Carcinoma; Osteosarcoma; T-ALL
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Posted: February 6th, 2018, 3:00pm GMT

Conditions: Breast Cancer; Colorectal Cancer; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant; Hepatocellular Carcinoma; Osteosarcoma; T-ALL
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting
PSMA-PET Imaging for Advanced ACC/SDC

Posted: October 24th, 2017, 2:00pm GMT

Conditions: Salivary Gland Cancer; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma
Intervention: Diagnostic Test: PSMA-PET/CT scan
Sponsors: Radboud University Medical Center; Adenoid Cystic Carcinoma Research Foundation
Completed
PSMA-PET Imaging for Advanced ACC/SDC

Posted: October 24th, 2017, 2:00pm GMT

Conditions: Salivary Gland Cancer; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma
Intervention: Diagnostic Test: PSMA-PET/CT scan
Sponsors: Radboud University Medical Center; Adenoid Cystic Carcinoma Research Foundation
Completed
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Posted: September 25th, 2017, 2:00pm GMT

Conditions: Melanoma (Skin); Squamous Cell Carcinoma of the Skin; Carcinoma, Squamous Cell of Head and Neck; Carcinoma, Adenoid Cystic
Interventions: Biological: CV8102; Biological: CV8102 + anti-PD-1 therapy
Sponsors: CureVac; Syneos Health; Cromos Pharma LLC
Active, not recruiting
MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial

Posted: September 19th, 2017, 2:00pm GMT

Conditions: Colorectal Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: TetMYB Vaccine; Drug: BGB-A317
Sponsor: Peter MacCallum Cancer Centre, Australia
Active, not recruiting
MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial

Posted: September 19th, 2017, 2:00pm GMT

Conditions: Colorectal Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: TetMYB Vaccine; Drug: BGB-A317
Sponsor: Peter MacCallum Cancer Centre, Australia
Active, not recruiting
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Posted: May 10th, 2017, 2:00pm GMT

Conditions: Major Salivary Gland Carcinoma; Minor Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVC Major Salivary Gland Carcinoma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsors: Northwestern University; Bristol-Myers Squibb; National Cancer Institute (NCI)
Unknown status
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Posted: March 22nd, 2017, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Radiation; Drug: Pembrolizumab
Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme LLC
Completed
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Posted: March 22nd, 2017, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Radiation: Radiation; Drug: Pembrolizumab
Sponsors: Dana-Farber Cancer Institute; Merck Sharp & Dohme LLC
Completed
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma

Posted: October 24th, 2016, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Interventions: Drug: Apatinib; Radiation: Particle Therapy
Sponsor: Shanghai Proton and Heavy Ion Center
Unknown status
Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Posted: August 30th, 2016, 2:00pm GMT

Condition: Adenocystic Carcinoma
Intervention: Drug: Chidamide
Sponsor: Dong mei
Unknown status
Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Posted: August 30th, 2016, 2:00pm GMT

Condition: Adenocystic Carcinoma
Intervention: Drug: Chidamide
Sponsor: Dong mei
Unknown status
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14

Posted: August 10th, 2016, 2:00pm GMT

Condition: Adenoid Cystic Carcinomas of the Salivary Glands
Intervention: Drug: Lenvatinib
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed
Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14

Posted: August 10th, 2016, 2:00pm GMT

Condition: Adenoid Cystic Carcinomas of the Salivary Glands
Intervention: Drug: Lenvatinib
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

Posted: August 8th, 2016, 2:00pm GMT

Condition: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib; Other: Observation
Sponsor: Seoul National University Hospital
Completed
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

Posted: August 8th, 2016, 2:00pm GMT

Condition: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib; Other: Observation
Sponsor: Seoul National University Hospital
Completed
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Posted: July 20th, 2016, 2:00pm GMT

Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Interventions: Radiation: Carbon ions therapy; Radiation: Advanced external radiotherapy by Xrays or protons
Sponsor: Hospices Civils de Lyon
Recruiting
Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Posted: July 20th, 2016, 2:00pm GMT

Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Interventions: Radiation: Carbon ions therapy; Radiation: Advanced external radiotherapy by Xrays or protons
Sponsor: Hospices Civils de Lyon
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 2:00pm GMT

Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Posted: July 15th, 2016, 2:00pm GMT

Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Malignant Neoplasm of Unknown Primary; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

Posted: May 23rd, 2016, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Lenvatinib
Sponsors: Memorial Sloan Kettering Cancer Center; Eisai Inc.
Active, not recruiting
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma

Posted: May 23rd, 2016, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Lenvatinib
Sponsors: Memorial Sloan Kettering Cancer Center; Eisai Inc.
Active, not recruiting
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Posted: May 17th, 2016, 2:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Apatinib Mesylate
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Unknown status
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

Posted: January 25th, 2016, 3:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Brontictuzumab
Sponsor: M.D. Anderson Cancer Center
Completed
Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

Posted: January 25th, 2016, 3:00pm GMT

Condition: Adenoid Cystic Carcinoma
Intervention: Drug: Brontictuzumab
Sponsor: M.D. Anderson Cancer Center
Completed
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Posted: April 25th, 2014, 2:00pm GMT

Conditions: Mucositis; Oral Complications; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Basal Cell Carcinoma of the Lip; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Salivary Gland Cancer; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Basal Cell Carcinoma of the Lip; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Salivary Gland Cancer; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Basal Cell Carcinoma of the Lip; Stage IVA Lymphoepithelioma of the Oropharynx; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Basal Cell Carcinoma of the Lip; Stage IVB Lymphoepithelioma of the Oropharynx; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Basal Cell Carcinoma of the Lip; Stage IVC Lymphoepithelioma of the Oropharynx; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Drug: acetylcysteine; Other: placebo; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Posted: April 25th, 2014, 2:00pm GMT

Conditions: Mucositis; Oral Complications; Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Basal Cell Carcinoma of the Lip; Recurrent Lymphoepithelioma of the Nasopharynx; Recurrent Lymphoepithelioma of the Oropharynx; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Basal Cell Carcinoma of the Lip; Stage I Lymphoepithelioma of the Nasopharynx; Stage I Lymphoepithelioma of the Oropharynx; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Salivary Gland Cancer; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Nasopharynx; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Basal Cell Carcinoma of the Lip; Stage II Lymphoepithelioma of the Nasopharynx; Stage II Lymphoepithelioma of the Oropharynx; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Salivary Gland Cancer; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Nasopharynx; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Basal Cell Carcinoma of the Lip; Stage III Lymphoepithelioma of the Nasopharynx; Stage III Lymphoepithelioma of the Oropharynx; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Lymphoepithelioma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Basal Cell Carcinoma of the Lip; Stage IVA Lymphoepithelioma of the Oropharynx; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Salivary Gland Cancer; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Basal Cell Carcinoma of the Lip; Stage IVB Lymphoepithelioma of the Oropharynx; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Salivary Gland Cancer; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Oropharynx; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Basal Cell Carcinoma of the Lip; Stage IVC Lymphoepithelioma of the Oropharynx; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Salivary Gland Cancer; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Oropharynx; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Drug: acetylcysteine; Other: placebo; Other: quality-of-life assessment; Other: questionnaire administration
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed

1 2 3

← Google - Adenoid Cystic Carcinoma Trial - Adenoid Cystic Carcinoma →

Rare Cancer News & Clinical Trials » PubMed - Adenoid Cystic Carcinoma

Feeds

PubMed - Adenoid Cystic Carcinoma (100 unread)

Fetched: January 13th, 2023, 2:04pm GMT by Junichi Shiraishi

Fetched: January 13th, 2023, 2:04pm GMT by Anand Kumar Das

Fetched: January 13th, 2023, 2:04pm GMT by Limin Gao

Fetched: January 12th, 2023, 5:00am GMT by Dandan Wang

Fetched: January 10th, 2023, 5:00am GMT by Weronika Jaremek-Ochniak

Fetched: January 9th, 2023, 5:00am GMT by Michael A Eisenberg

Fetched: January 3rd, 2023, 5:00am GMT by Cong-Gai Huang

Fetched: January 3rd, 2023, 5:00am GMT by Mengjiao Zhou

Fetched: December 28th, 2022, 5:00am GMT by Fei Xu

Fetched: December 27th, 2022, 5:00am GMT by H Ishikawa

Fetched: December 25th, 2022, 5:00am GMT by Shengwen Liu

Fetched: December 23rd, 2022, 5:00am GMT by Wenna Zhang

Fetched: December 23rd, 2022, 5:00am GMT by Jiyi Hu

Fetched: December 22nd, 2022, 5:00am GMT by Hyat Ahmed Ibrahim Al-Raimi

Fetched: December 22nd, 2022, 5:00am GMT by Christian Krauss

Fetched: December 20th, 2022, 5:00am GMT by Yudi Han

Fetched: December 18th, 2022, 5:00am GMT by Jérôme Estephan

Fetched: December 17th, 2022, 5:00am GMT by Kaitlyn D W Ooms

Fetched: December 16th, 2022, 5:00am GMT by Bing Zhang

Fetched: December 16th, 2022, 5:00am GMT by Rajat Jain

Posted: September 23rd, 2022, 2:00pm GMT

Posted: September 23rd, 2022, 2:00pm GMT

Posted: August 12th, 2022, 2:00pm GMT

Posted: August 12th, 2022, 2:00pm GMT

Posted: January 18th, 2022, 3:00pm GMT

Posted: January 18th, 2022, 3:00pm GMT

Posted: October 12th, 2021, 2:00pm GMT

Posted: October 12th, 2021, 2:00pm GMT

Posted: August 18th, 2021, 2:00pm GMT

Posted: August 18th, 2021, 2:00pm GMT

Posted: July 23rd, 2021, 2:00pm GMT

Posted: July 23rd, 2021, 2:00pm GMT

Posted: July 22nd, 2021, 2:00pm GMT

Posted: July 22nd, 2021, 2:00pm GMT

Posted: May 12th, 2021, 2:00pm GMT

Posted: May 12th, 2021, 2:00pm GMT

Posted: April 5th, 2021, 2:00pm GMT

Posted: April 5th, 2021, 2:00pm GMT

Posted: March 16th, 2021, 2:00pm GMT

Posted: March 16th, 2021, 2:00pm GMT

Posted: January 13th, 2021, 3:00pm GMT

Posted: January 13th, 2021, 3:00pm GMT

Posted: June 16th, 2020, 2:00pm GMT

Posted: June 16th, 2020, 2:00pm GMT

Posted: March 2nd, 2020, 3:00pm GMT

Posted: March 2nd, 2020, 3:00pm GMT

Posted: January 31st, 2020, 3:00pm GMT

Posted: January 31st, 2020, 3:00pm GMT

Posted: January 2nd, 2020, 3:00pm GMT

Posted: January 2nd, 2020, 3:00pm GMT

Posted: December 24th, 2019, 3:00pm GMT

Posted: December 24th, 2019, 3:00pm GMT

Posted: October 28th, 2019, 2:00pm GMT

Posted: October 28th, 2019, 2:00pm GMT

Posted: October 8th, 2019, 2:00pm GMT

Posted: October 8th, 2019, 2:00pm GMT

Posted: July 22nd, 2019, 2:00pm GMT

Posted: July 22nd, 2019, 2:00pm GMT

Posted: June 27th, 2019, 2:00pm GMT

Posted: June 27th, 2019, 2:00pm GMT

Posted: June 19th, 2019, 2:00pm GMT

Posted: June 19th, 2019, 2:00pm GMT

Posted: March 22nd, 2019, 2:00pm GMT

Posted: March 22nd, 2019, 2:00pm GMT

Posted: December 20th, 2018, 3:00pm GMT

Posted: December 20th, 2018, 3:00pm GMT

Posted: October 1st, 2018, 2:00pm GMT

Posted: October 1st, 2018, 2:00pm GMT

Posted: August 21st, 2018, 2:00pm GMT

Posted: August 21st, 2018, 2:00pm GMT

Posted: June 14th, 2018, 2:00pm GMT

Posted: June 14th, 2018, 2:00pm GMT

Posted: February 6th, 2018, 3:00pm GMT